<DOC>
	<DOC>NCT01756924</DOC>
	<brief_summary>To determine if oral antibiotic treatment with CEM-102 and Rifampin is as effective and safe as the standard of care antibiotic therapy for the treatment of hip and knee prosthetic joint or spacer infections</brief_summary>
	<brief_title>Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Arthritis, Infectious</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<mesh_term>Levofloxacin</mesh_term>
	<mesh_term>Fusidic Acid</mesh_term>
	<criteria>Prosthetic knee or hip joint infection Infected joint spacer Able to swallow tablets Able to voluntarily sign the informed consent form Females of childbearing potential must use an acceptable method of birth control The joint infection must be attributed to bacterial pathogens sensitive to fusidic acid and rifampin History of hypersensitivity or intolerability to sodium fusidate (FucidinÂ®), or to rifampin Females who are pregnant or lactating Requirement for significant immunosuppression Bacteremia Known cirrhosis or decompensated liver disease Current treatment for HIV or Hepatitis C Seizure disorder, requiring anticonvulsants</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>prosthetic joint infection</keyword>
	<keyword>hip arthroplasty</keyword>
	<keyword>MRSA</keyword>
	<keyword>knee arthroplasty</keyword>
</DOC>